Merck To Build Case For Doravirine-Based HIV Products On Efficacy, Safety Differences
Merck adds to its stagnating HIV portfolio with US approvals of doravirine and a three-drug combo including the NNRTI, but the combo’s potential may be limited due to inclusion of an older version of tenofovir.
You may also be interested in...
First-in-class antiviral could be a potential backbone for combo regimens and entry into PrEP. New data releases at IAS highlight potential in both settings.
Keytruda continues to break records on the strength of its efficacy in lung cancer, and shows no signs of slowing down. But analysts were intrigued by repeated mentions of business development during Merck’s third quarter earnings call.
With Merck and Bristol-Myers Squibb at the head of the immuno-oncology class – and jockeying for the lead – the two companies are reporting third quarter earnings in back-to-back calls on Oct. 25. Oncology has become dominant for both businesses, and analysts are keen for nuances to help differentiate the growth potential for the two firms.